Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease.

ABSTRACT:

Background

Autosomal-dominant polycystic kidney disease (ADPKD) is characterized by multitudes of expanding renal cysts associated with mononuclear interstitial infiltrates. Monocyte chemotactic protein-1 is produced in the kidneys and excreted in the urine (uMCP1) of these patients in increased amounts. In the TEMPO 3:4 trial, tolvaptan slowed the rate of increase in total kidney volume (TKV) and the rate of decline in estimated glomerular filtration rate (eGFR). In a sub-analysis, we determined whether tolvaptan administration for up to 3 years changed the urinary excretion of MCP-1 referenced to creatinine in 869 treated subjects compared with 438 placebo subjects.

Methods

Treatment group differences of uMCP1 at 0.75, 12, 24 and 36 months were evaluated by ANCOVA with fac

SUBMITTER: Grantham JJ 

PROVIDER: S-EPMC5837351 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature